Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04388683 · ClinicalTrials.gov registry record · Phase 2
Inhaled Nitric Oxide for Preventing Progression in COVID-19
A Phase 2 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04388683 is a Phase 2 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04388683, a Phase 2 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of age \> 60 years, type II DM, hypertension, and obesity.
Interventions
- DRUG Nitric Oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-05-12 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04388683
The ClinicalTrials.gov registry entry for NCT04388683 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nitric Oxide is the first listed.
NCT04388683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04388683 about?
NCT04388683 is a clinical study titled "Inhaled Nitric Oxide for Preventing Progression in COVID-19". This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of age \> 60 years, type...
What is the current status of trial NCT04388683?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-05-12. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT04388683?
The interventions under investigation include: Nitric Oxide (DRUG).
Who is sponsoring clinical trial NCT04388683?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.